Biovitrum merges with Swedish Orphan in $493M deal

Sweden's Biovitrum has snapped up Swedish Orphan in a $493 million deal. The merger will create Swedish Orphan Biovitrum, marrying Orphan's business and marketing savvy with Biovitrum's development skills on orphan and niche drugs.

"The two companies fit like a hand in a glove," Biovitrum said. "In one giant leap we form a company with a leading position within rare diseases and a solid platform for future growth and profitability."

"Along with Biovitrum's product portfolio and late stage pipeline, we can further leverage Swedish Orphan's strong platform in a value creating manner while continuing both companies' commitment to rare disease patients and patients with unmet medical needs," says Swedish Orphan CEO Bo Jesper Hansen.

- check out the Biotvitrum release
- here's the Reuters story

Suggested Articles

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.

Chinook Therapeutics is set to merge with fallen Big Pharma darling Aduro Biotech to create a kidney disease player with $180 million in cash.